Atovaquone and proguanil for the treatment of malaria in Brazil.
The purpose of this study was to compare an experimental regimen of atovaquone plus proguanil with the standard regimen of quinine plus tetracycline for the treatment of uncomplicated falciparum malaria. The study was designed as an open, randomized study of men presenting with symptoms of uncomplicated malaria and thick-smear slide confirmation of parasitemia (1000-100,000 ring forms/microL). Subjects were hospitalized for 28 days to insure medication compliance and to rule out the possibility of reinfections. With 77 patients in each group, the cure rates were 98.7% and 100% for atovaquone plus proguanil and quinine plus tetracycline, respectively. The parasite clearance times (mean, 56 h) and fever clearance times (mean, 19 h) were significantly shorter in the atovaquone plus proguanil group, and there were significantly fewer side effects in the atovaquone plus proguanil group. Atovaquone plus proguanil is an efficacious, easily administered, safe regimen for the treatment of uncomplicated, multidrug-resistant falciparum malaria in Brazil.
de Alencar
F E
FE
Universidade de São Paulo, and United States Army Medical Research Unit, Brazil.
Cerutti
C
C
Durlacher
R R
RR
Boulos
M
M
Alves
F P
FP
Milhous
W
W
Pang
L W
LW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000962:Antimalarials / Q000008:administration & dosage* / Q000009:adverse effects; D053626:Atovaquone; D001938:Brazil; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009285:Naphthoquinones / Q000008:administration & dosage* / Q000009:adverse effects; D002727:Proguanil / Q000008:administration & dosage* / Q000009:adverse effects; D011803:Quinine / Q000008:administration & dosage / Q000009:adverse effects; D013752:Tetracycline / Q000008:administration & dosage / Q000009:adverse effects
D000962:Antimalarials; D009285:Naphthoquinones; D011803:Quinine; D013752:Tetracycline; D002727:Proguanil; D053626:Atovaquone